ACXP, US00510M2035

Alliance Global Partners reiterates USD 10.00 target for Acurx stock

Published on 10/06/2026 at 09:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Alliance Global Partners reiterates a USD 10.00 target for Acurx stock. Acurx posted a USD 2.3 million net loss in the second quarter of 2026.

ACXP, US00510M2035, Illustration mit AI erstellt.

Acurx Pharmaceuticals (ISIN US00510M2035) remains tied to a USD 10.00 analyst target after Stock Analysis reported on September 30, 2026, that Alliance Global Partners reiterated its Buy rating and USD 10.00 target. The update followed Acurx's September 29 announcement that the first patient had entered its PATHFINDER trial.

PATHFINDER reaches its first patient

According to Acurx Pharmaceuticals on September 29, 2026, PATHFINDER is a Phase 2 study of ibezapolstat in patients with multiply recurrent Clostridioides difficile infection. The open-label, single-arm trial will assess treatment response, safety and recurrence outcomes through 24 weeks.

The company said the study is fully funded and is intended to support a potential regulatory path for treatment and prevention of recurrent infection. Acurx also said its planned ASPIRE Phase 3 program remains subject to funding, making financing an important operational variable for the development timeline.

Losses keep the funding question central

Acurx reported a consolidated net loss of USD 2.3 million in the second quarter of 2026, compared with USD 2.2 million in the second quarter of 2025, according to Scanx. The first-half 2026 net loss was USD 3.9 million, compared with USD 4.4 million in the first half of 2025.

Cash stood at USD 10.7 million on June 30, 2026, up from USD 7.6 million at December 31, 2025. Research and development expense rose to USD 1.1 million in the second quarter of 2026 from USD 0.5 million in the comparable quarter, while the company raised USD 2.5 million through financing during the quarter.

Small capitalization, wide trading range

Acurx had a market capitalization of USD 5.6 million on October 5, 2026. Its 52-week range was USD 1.23 to USD 8.34, leaving the analyst target materially above the quoted range and keeping clinical execution and financing central to the stock story.

Acurx Pharmaceuticals is listed on NASDAQ under ticker ACXP. Its lead candidate ibezapolstat targets bacterial DNA polymerase IIIC, a development strategy aimed at difficult-to-treat infections.